Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Genomica Merger Passes End of Initial Offering Period

SAN FRANCISCO, Jan. 2 - The proposed Genomica-Exelixis merger reached the close of its initial offering period for the exchange of its stock on Dec. 28 at Eastern Standard Time, Exelixis said on Wednesday.


The companies set the ratio for converting shares of Genomica stock into shares of Exelixis stock at 0.28309 at the initial offering period's close.


Exelixis announced on Nov. 19 plans to acquire Genomica in a stock deal valued at $110 million, and Genomica's board of directors unanimously recommended that the firm's stockholders accept the offer, according to the company.

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.